

# Xintela proposes Thomas Elderred as new Board member

**Major shareholder in Xintela AB (publ) proposes that the company's shareholders elect Thomas Elderred as a new member of the Board at the Extra General Meeting on November 28, 2022.**

The board of directors announces the proposal regarding election of new Board member at the Extra General Meeting on November 28, 2022. The company's major shareholder proposes that Thomas Elderred is elected member of the Board for the time until the next annual general meeting.

Thomas Elderred, born in 1960, is the founder and main owner of Flerie Invest AB, which holds 40.7 percent of the shares and votes in Xintela. Thomas Elderred was also co-founder of Recipharm AB, where he served as CEO from 2008 to 2021. He is currently chairman of the board of Amarna Therapeutics BV, NorthX Biologics AB and Prokarium Ltd, and a member of the Board of Buzzard Pharmaceuticals AB, Chromafora AB, Flerie Invest AB, Kahr Bio Ltd, Nanologica AB, Toleranzia AB and Sixera Pharma AB, among others. Thomas holds a Master of Science in Industrial Engineering and Management from Linköping University.

*"Thomas is one of Sweden's most successful and experienced entrepreneurs, executives and investors in life sciences. It is an affirmation of Xintela's excellent growth and development that Flerie Invest and Thomas have joined us as we strive to achieve significant milestones ahead. It gives me great pleasure to welcome Thomas to our Board of Directors on behalf of the entire company",* says Xintela's Chairman of the Board Gregory Batcheller.

## Contacts

---

### **Xintela AB (publ)**

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: [evy@xintela.se](mailto:evy@xintela.se)

Medicon Village

223 81 Lund, Sweden

[www.xintela.se](http://www.xintela.se)



---

## About Xintela

---

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin  $\alpha 10\beta 1$  which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin  $\alpha 10\beta 1$  (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).

## Attachments

---

[Xintela proposes Thomas Elderer as new Board member](#)